Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth
Abstract Sphingosine kinases (SphK), including SphK1 and SphK2, are important enzymes promoting progression of prostate cancer. SKI-178 is a novel and highly potent SphK1/2 dual inhibitor. We here tested the potential anti-prostate cancer cell activity of SKI-178. Bioinformatics analyses and results...
Main Authors: | Lu Jin, Jin Zhu, Linya Yao, Gang Shen, Bo-xin Xue, Wei Tao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-08-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-023-06023-4 |
Similar Items
-
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
by: Yanhong Bu, et al.
Published: (2021-10-01) -
Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
by: Weiwei Shi, et al.
Published: (2020-06-01) -
The role of SphK/S1P/S1PR signaling pathway in bone metabolism
by: Xuefeng Xu, et al.
Published: (2023-12-01) -
Activation of SphK2 contributes to adipocyte-induced EOC cell proliferation
by: Dai Lan, et al.
Published: (2022-01-01) -
Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19
by: Eileen M McGowan, et al.
Published: (2020-09-01)